UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Generation of conditional oncogenic chromosomal translocations using CRISPR–Cas9 genomic editing and homology‐directed repair

The Journal of pathology, 2017-05, Vol.242 (1), p.102-112

2017

Volltextzugriff (PDF)

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

Cancer research (Chicago, Ill.), 2015-03, Vol.75 (6), p.1035-1045

2015

Volltextzugriff (PDF)

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Cancer discovery, 2015-08, Vol.5 (8), p.842-849

2015

Volltextzugriff (PDF)

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Disease models & mechanisms, 2010-01, Vol.3 (1-2), p.111-119

2010

Volltextzugriff (PDF)

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

Genes & development, 2006-06, Vol.20 (11), p.1496-1510

2006

Volltextzugriff (PDF)

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.516-526

2023

Volltextzugriff (PDF)

ERBBal Remedies: Combination Therapy for EGFR -mutant Lung Cancers

Clinical cancer research, 2018-11, Vol.24 (22), p.5499-5501

2018

Volltextzugriff (PDF)

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI

Future oncology (London, England), 2024-05, Vol.20 (15), p.969-980

2024

Volltextzugriff (PDF)

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR -mutated NSCLC

Future oncology (London, England), 2023-06, Vol.19 (19), p.1319-1329

2023

Volltextzugriff (PDF)

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

Proceedings of the National Academy of Sciences - PNAS, 2018-06, Vol.115 (26), p.E6030-E6038

2018

Volltextzugriff (PDF)

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Nature communications, 2024-07, Vol.15 (1), p.5826-13, Article 5826

2024

Volltextzugriff (PDF)

The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway

The Journal of experimental medicine, 1997-12, Vol.186 (12), p.1947-1955

1997

Volltextzugriff (PDF)

Abl Interactor 1 Binds to Sos and Inhibits Epidermal Growth Factor- and v-Abl-Induced Activation of Extracellular Signal-Regulated Kinases

Molecular and Cellular Biology, 2000-10, Vol.20 (20), p.7591-7601

2000

Volltextzugriff (PDF)

Homo- and hetero-oligomerization of the c-Abl kinase and abelson-interactor-1

Cancer research (Chicago, Ill.), 2003-02, Vol.63 (4), p.873-877

2003

Volltextzugriff (PDF)

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Genes & development, 2006-06, Vol.20 (11), p.1496-1510

2006

Volltextzugriff (PDF)

Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR -mutated NSCLC

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3161-TPS3161

2022

Volltextzugriff (PDF)

EN2-5. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in NSCLC without EGFR-activating mutations

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.561-561

2022

Volltextzugriff (PDF)

Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9607-9607

2020

Volltextzugriff (PDF)

HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3588-3588

2022

Volltextzugriff (PDF)

PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC

Annals of oncology, 2023-11, Vol.34, p.S1379-S1379

2023

Volltextzugriff (PDF)

Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228

Journal of thoracic oncology, 2022-10, Vol.18 (4), p.516-526

2022

Volltextzugriff (PDF)

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR -activating mutations

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9017-9017

2022

Volltextzugriff (PDF)

YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21591-e21591

2020

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(39)
Dissertationen
(1)

Sprache

Englisch
(39)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Generation of conditional oncogenic chromosomal translocations using CRISPR–Cas9 genomic editing and homology‐directed repair

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

ERBBal Remedies: Combination Therapy for EGFR -mutant Lung Cancers

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR -mutated NSCLC

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway

Abl Interactor 1 Binds to Sos and Inhibits Epidermal Growth Factor- and v-Abl-Induced Activation of Extracellular Signal-Regulated Kinases

Homo- and hetero-oligomerization of the c-Abl kinase and abelson-interactor-1

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR -mutated NSCLC

EN2-5. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in NSCLC without EGFR-activating mutations

Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations

HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target

PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC

Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR -activating mutations

YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)

Suchergebnisse filtern